bioAffinity Technologies (BIAF) furnishes February 2026 presentation materials in 8-K
Rhea-AI Filing Summary
bioAffinity Technologies, Inc. filed a current report to furnish updated presentation materials about the company’s operations and performance. Management intends to use these February 2026 presentation slides in meetings, and the materials were posted to the company’s website on February 10, 2026.
The materials are furnished under Regulation FD as Exhibit 99.1 and are expressly not deemed “filed” for liability purposes under the Securities Exchange Act of 1934 or incorporated by reference into other Securities Act or Exchange Act filings.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||
|
|
|
(Nasdaq Capital Market) | |
(Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure.
bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time in presentations about the Company’s operations and performance. The Presentation Materials were posted to the Company’s website on February 10, 2026. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit Number |
Description | |
| 99.1 | Presentation Materials – February 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: February 10, 2026 | BIOAFFINITY TECHNOLOGIES, INC. | |
| By: | /s/ Maria Zannes | |
| Name: | Maria Zannes | |
| Title: | President and Chief Executive Officer | |
| -3- |
Exhibit 99.1
FAQ
What did bioAffinity Technologies (BIAF) disclose in this 8-K filing?
How are the bioAffinity Technologies (BIAF) presentation materials treated legally?
Where can investors find bioAffinity Technologies’ February 2026 presentation?
Which securities of bioAffinity Technologies (BIAF) are listed on Nasdaq?
Who signed the February 10, 2026 bioAffinity Technologies 8-K?
Filing Exhibits & Attachments
25 documentsPress Releases
- EX-99.1 EX-99.1 21.6 KB
- EX-99 GRAPHIC 55.2 KB
- EX-99 GRAPHIC 158.2 KB
- EX-99 GRAPHIC 129.4 KB
- EX-99 GRAPHIC 97.9 KB
- EX-99 GRAPHIC 128.5 KB
- EX-99 GRAPHIC 139.8 KB
- EX-99 GRAPHIC 139.7 KB
- EX-99 GRAPHIC 102.0 KB
- EX-99 GRAPHIC 84.3 KB
- EX-99 GRAPHIC 78.0 KB
- EX-99 GRAPHIC 101.3 KB
- EX-99 GRAPHIC 104.2 KB
- EX-99 GRAPHIC 83.6 KB
- EX-99 GRAPHIC 73.5 KB
- EX-99 GRAPHIC 92.9 KB
- EX-99 GRAPHIC 89.3 KB
- EX-99 GRAPHIC 111.0 KB
- EX-99 GRAPHIC 121.7 KB
- EX-99 GRAPHIC 113.5 KB
- EX-99 GRAPHIC 56.1 KB
